Imdur

Quick links to important sections

Imdur

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Imdur

Quick Facts: Isosorbide Mononitrate

Property Description
Active Ingredient Isosorbide Mononitrate (ISMN)
Form Extended-Release (ER) Oral Tablet
Pharmacological Class Organic Nitrate / Vasodilator
Common Use Long-term cardiovascular maintenance therapy
Origin Synthetic Compound

What Type of Drug is Isosorbide Mononitrate?

The medication containing the active ingredient Isosorbide Mononitrate (ISMN) is a synthetic, prescription-only compound. It is primarily classified as an Antianginal Agent and belongs to the specific pharmacological class of Organic Nitrates. This designation is due to its function as a potent Vasodilator, which helps prevent symptoms associated with coronary artery conditions.

Isosorbide Mononitrate is a single-ingredient organic molecule that is the major biologically active metabolite of the older drug isosorbide dinitrate. This characteristic ensures near-complete and predictable bioavailability compared to its precursor, a feature that makes it highly suitable for consistent daily management.

Composition and Available Tablet Form

This medication is a single-ingredient product designed for the oral route of administration, consisting of the active compound and pharmaceutical excipients formulated into a compressed tablet. While standard tablets exist, the most commonly prescribed form is the Extended-Release (ER) oral tablet, sold under brand names like Imdur.

This Extended-Release design is intended for maintaining a steady, therapeutic concentration of the drug in the body over many hours. By ensuring sustained delivery of the active substance, this specialized formulation provides continuous cardiovascular support and avoids the rapid fluctuations associated with immediate-release dosing.

What is the General Purpose of This Vasodilator?

The general purpose of this organic nitrate is to fundamentally reduce the workload and strain on the heart muscle. Its action as a systemic Vasodilator causes the smooth muscles in blood vessels to relax, widening them and improving overall blood flow.

This vasodilatory effect achieves its therapeutic benefit by decreasing the pressure and volume of blood returning to the heart (reducing preload) and lessening the resistance the heart must pump against (reducing afterload). This reduction in cardiac effort positions Isosorbide Mononitrate as a foundational component in long-term cardiovascular maintenance therapy.

Regulatory References

  1. Isosorbide - StatPearls - NCBI Bookshelf
  2. Isosorbide Mononitrate Extended-Release Tablet Label - DailyMed

What side effects are possible with Imdur?

Possible Side Effects and Safety Information

The safety profile of isosorbide mononitrate is based on its primary function as a potent vasodilator, and officially documented adverse events are categorized by frequency and the body system affected, according to regulatory labels.


Adverse Reactions by Frequency and Organ System

The most frequent adverse reaction is headache, which is classified as Very Common (1/10 of patients) in regulatory documents. This effect is often transient and typically most prominent at the start of treatment, usually subsiding with continued therapy.

Reactions classified as Common (1/100 to < 1/10 of patients) primarily involve the vascular and nervous systems. These include dizziness, hypotension (low blood pressure, including postural hypotension), nausea, and tachycardia (increased heart rate). Like headache, these effects are more frequently observed at the beginning of therapy.

Uncommon effects (1/1,000 to < 1/100 of patients) include vomiting, diarrhoea, flushing, and allergic skin reactions. Rare or very rare effects include syncope (fainting), rash, and pruritus.


Serious Safety Restrictions

Official labeling documents emphasize several safety constraints. Severe hypotension is a serious adverse reaction that can potentially lead to states of circulatory collapse. The medication is strictly contraindicated in patients with marked hypotension (systolic blood pressure leq 90 mmHg) and acute circulatory failure.

The drug must not be used for the relief of an acute angina attack, as it is indicated only for long-term preventative management. Furthermore, the co-administration of Imdur with Phosphodiesterase type 5 (PDE-5) inhibitors (such as sildenafil) is absolutely contraindicated due to the risk of life-threatening severe hypotension.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of isosorbide mononitrate is characterized by manifestations linked to excessive systemic vasodilatation, requiring immediate medical attention. The officially documented clinical signs of overdose primarily include severe hypotension (low blood pressure), which may be accompanied by confusion, syncope, vertigo, or a persistent, throbbing headache. Other presentations described in regulatory labeling include palpitations, tachycardia, flushing, and gastrointestinal symptoms like nausea and vomiting.

Severe Outcomes and Emergency Response

Overdose situations carry the risk of severe, life-threatening outcomes, notably methemoglobinemia, which can lead to cyanosis, respiratory depression, and subsequent circulatory failure. Increased intracranial pressure is also documented as a potential complication.

Regulatory documents mandate that immediate medical help be sought for treatment. While there is no specific antagonist known for the vasodilator effects, supportive management is required. This often involves measures to increase central fluid volume, such as the passive elevation of the patient's legs and intravenous infusion of fluids. The official guidance warns that the use of epinephrine or other arterial vasoconstrictors is likely to do more harm than good. Furthermore, hospital monitoring and observation for at least 12 hours are required. Treatment in patients with coexisting renal disease or congestive heart failure is described as being particularly troublesome and difficult.

Therapeutic Uses of Imdur

What Imdur treats: main uses and benefits

Imdur (isosorbide mononitrate) is commonly used across conditions presenting with acute episodes, specifically for the management of chronic stable angina pectoris. As an official indication, this medication is relevant for easing symptoms linked to organ-specific functional stress, specifically the chest discomfort associated with coronary artery disease. The core function is applied across domains where additional symptomatic support is needed to help manage these issues.

The medication is applied in addressing symptoms related to physical discomfort, and it may assist with reducing the frequency of episodes where symptoms become more disruptive during flare-ups. This long-term approach contributes to improved comfort by reducing the strain from recurrent events. The benefit is preventative, and isosorbide mononitrate is indicated for the prevention of angina pectoris due to coronary artery disease.

It is important to understand that this medicine is used for long-term symptom management, not for relief of an acute, ongoing episode. It is considered relevant for easing symptoms associated with acute or episodic changes. The overall goal supports the patient during difficult episodes by easing the symptomatic burden.

Quick Fact: Relief for Physical Discomfort

Regulatory References

  1. NIH DailyMed Official Drug Label

Eligibility and Restrictions for Use

The eligibility for using Imdur (isosorbide mononitrate) is strictly defined by government regulatory labeling, which outlines populations that are permitted, restricted, or prohibited from use. Adults are the primary eligible population for the prevention of chronic stable angina pectoris.

Absolute Non-Eligibility (Contraindications)

Use is contraindicated in patients with a known hypersensitivity to any nitrate, including isosorbide mononitrate. The medicine must not be used by any patient taking Phosphodiesterase Type 5 (PDE5) Inhibitors (e.g., sildenafil) or Soluble Guanylate Cyclase (sGC) Stimulators (e.g., riociguat) due to the risk of severe hypotension. Contraindications also include conditions such as severe anemia and acute circulatory failure or shock.

Use Limitations and Restrictions

Population / Condition Regulatory Status
Pediatric Population Safety and efficacy have not been established in children.
Pregnant Women Safety is not established; use only if potential benefits outweigh risks.
Lactating Women Caution should be exercised; excretion into human milk is unknown.
Severe Organ Impairment Special care is required in patients with marked hepatic or renal insufficiency.
Hypotension/HCM Use with caution in patients who are hypotensive or have hypertrophic cardiomyopathy.

These official rules determine who can or cannot use the medicine, focusing on defined risk profiles and established data limitations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Imdur (isosorbide mononitrate) defines interactions primarily based on additive pharmacodynamic effects, which increase the risk of severely low blood pressure.

Interaction Type Interacting Products/Classes Regulatory Status
Contraindicated Combinations Phosphodiesterase Type 5 (PDE-5) Inhibitors (e.g., sildenafil, tadalafil, vardenafil, avanafil) Strictly Forbidden
Soluble Guanylate Cyclase (sGC) Stimulator (Riociguat) Strictly Forbidden
Use with Caution Other Vasodilators (e.g., calcium channel blockers, other nitrates) Additive Hypotension Risk
Substance Interaction Alcohol (Ethanol) Additive Hypotension Risk

Co-administration with PDE-5 inhibitors or sGC stimulators is absolutely contraindicated due to the mechanism of additive vasodilation, which results in a severe and potentially life-threatening drop in blood pressure. The vasodilating effects may also be additive with other classes of blood pressure-lowering agents and organic nitrates, necessitating careful assessment of concurrent use. Similarly, co-administration with alcohol has been found to exhibit these same additive vasodilating effects, increasing the risk of symptoms related to severe postural hypotension. This structure emphasizes mandatory do-not-combine rules rather than pharmacokinetic constraints, reflecting the product's primary interaction risk.

Mechanism of Action

Nitric Oxide Release and Vascular Smooth Muscle Relaxation

This drug functions as a prodrug that is metabolized to its active metabolite, isosorbide-5-mononitrate. This metabolite releases nitric oxide (NO), a gaseous signaling molecule, which activates the enzyme soluble Guanylate Cyclase (sGC) within the smooth muscle cells of blood vessel walls. This intracellular action increases the concentration of cyclic Guanosine Monophosphate (cGMP), triggering a cascade that results in the relaxation and widening (vasodilation) of the vascular smooth muscle, primarily affecting the venous system.

Modulating Cardiac Preload and Afterload

The resulting widespread vasodilation reduces the volume of blood returning to the heart’s chambers (lowered cardiac preload). Concurrently, dilation of arteries reduces the resistance the heart must overcome to eject blood (lowered cardiac afterload). This modulation of preload and afterload decreases the stretching and tension on the heart muscle walls, which reduces the energetic requirements of the myocardium. The responsiveness of this pathway can diminish with continuous presence of the active metabolite, a process referred to as tolerance or tachyphylaxis.

Dosage and Administration Information

The extended-release formulation of isosorbide mononitrate (Imdur) is designated for oral administration and follows a specific, time-dependent regimen.

Administration Principles and Dosage

The standard adult dosing regimen involves a single tablet taken once daily. This frequency is necessary for maintaining a nitrate-low period in the body, a structural element designed to prevent the development of pharmacological tolerance. The usual starting dose is 30 mg or 60 mg once daily.

After assessment over several days, the dose may be increased to a standard maximum of 120 mg once daily; in certain cases, 240 mg may be required. The dose is administered in the morning upon arising.

Procedural Constraints

The administration method is critical due to the Extended-Release nature of the medicine. The tablet must be swallowed whole with a drink of water and must not be crushed, split, or chewed. This physical constraint ensures the active substance is released slowly over the intended period.

For older patients, treatment typically begins at the low end of the dose range. Furthermore, treatment should not be stopped suddenly; instead, the dosage and frequency must be tapered gradually to discontinue use.

Recent Clinical Evidence

Imdur: Recent Clinical Evidence

Evidence for Use in Preventing Chronic Stable Angina

Research for isosorbide mononitrate has primarily focused on its official indication: the long-term prophylaxis of chronic stable angina (chest discomfort) due to coronary artery disease. Studies conducted for this purpose are primarily Randomized Controlled Trials (RCTs). These are research formats where participants are randomly assigned to receive either the medicine or a comparison treatment, often an inactive pill (placebo), to observe patterns related to physical discomfort over defined time intervals.

Researchers evaluated how this medicine was studied for people with established chronic stable angina. The outcomes they monitored included patient-reported experiences, such as the frequency of anginal attacks over a week, patient records of emergency relief medication consumption, and measurements of a person’s exercise duration and tolerance using stress tests. The findings from these trials describe patterns observed in the study data, which included measurements showing changes in exercise capacity and physiological strain during exertion.

⏳ Long-Term Studies and the Role of Nitrate Tolerance

Research has explored the durability of the antianginal effect over intermediate timeframes, generally spanning several months to a year or more. The research examined how reliably symptom patterns were observed in the study populations during the treatment period. The key limitation studied in the context of long-term use is nitrate tolerance. This is a phenomenon where the body may adapt to continuous exposure, which was associated with challenges in maintaining the measured anti-ischemic effort.

Studies focused heavily on regimens that incorporate a daily break from the medication. Limited information for long-term outcomes beyond relief of physical discomfort is available. Data extending beyond one year, on major clinical events associated with the medicine (such as hospitalization or survival) were not the primary endpoints of the existing antianginal studies.

What is Still Uncertain About Isosorbide Mononitrate

Despite a clear body of RCT evidence for its use in preventing angina, certain aspects remain uncertain. Research in other contexts, such as heart failure, showed findings that were mixed regarding whether physiological measurements translated into sustained improvements in a patient's exercise capacity. The clinical context of these findings remains an area where data are still emerging and certainty remains low. Furthermore, data for certain groups remain insufficient, including evidence for children and patients with multiple complex or rapidly changing health issues.

Key Studies & References

  1. Isosorbide Mononitrate Extended Release Tablets Official Labeling (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Imdur (FAQ)

Q: What is the difference between Imdur (Isosorbide Mononitrate) and nitroglycerin (GTN)?

A: According to official product information, Imdur is a long-term maintenance medication used for the prevention of chronic stable angina. Its action is not rapid enough to stop sudden chest discomfort. For the treatment of an acute angina attack, sublingual glyceryl trinitrate (nitroglycerin) is the recommended treatment to be used.


Q: How long do the common side effects, such as headache or dizziness, usually last after starting Imdur?

A: Official regulatory sources note that headaches are very common when beginning Imdur treatment. These headaches are often transient and typically subside within the first 1 to 2 weeks of continued therapy. Other common side effects, like dizziness, are also more frequently observed at the start of treatment.


Q: Are there any specific foods or drinks that should be avoided when taking Imdur?

A: Official guidance indicates that patients should discuss alcohol consumption with their healthcare provider, as it can worsen certain side effects, particularly low blood pressure. The official instruction is generally to continue a normal diet unless otherwise directed by a healthcare professional.


Q: What is the distinction between Imdur being used for stable versus unstable angina?

A: Imdur is indicated solely for the long-term prevention of chronic stable angina, which is chest discomfort that follows a predictable pattern. Official product information clarifies that this medication is not for the treatment of an acute (sudden) angina attack.


Q: What do research studies indicate about the overall long-term safety profile of Imdur?

A: Research has examined the antianginal effect of the drug over long periods, primarily focusing on the potential development of nitrate tolerance. Official documents indicate that studies measuring long-term major clinical events, such as hospitalization or survival, were not the primary focus of the existing antianginal trials.


Q: What kind of symptoms should prompt a person to seek immediate medical attention while on Imdur?

A: Official product information advises that symptoms of severe allergic reaction (such as hives, difficulty breathing, or swelling of the face, lips, or throat) may warrant emergency medical attention. This action is also advised for symptoms that may suggest a heart attack, including chest pain/pressure spreading to the jaw or shoulder, or sweating.


Q: What is the connection between Imdur and feeling extremely tired or fatigued?

A: Feeling weak or extremely tired is listed in official documentation as a potential symptom of low blood pressure, which is a known effect of this class of medication. Official information suggests discussing this symptom with a healthcare provider if it occurs.


Q: Do headaches on Imdur indicate that the medication is working properly?

A: Official regulatory information states that the daily headaches that sometimes occur when initiating treatment are considered a marker of the drug’s activity. Patients are advised that these headaches are transient and typically fade after a few weeks of continued use.


Q: Is it possible to see an undigested tablet shell in the stool after taking Imdur ER?

A: The extended-release formulation utilizes a core matrix that is insoluble in the body's digestive juices. Official product information states that this matrix may very occasionally pass through the gastrointestinal tract and be visible in the stool after the active substance has been completely released.


Q: Are there any reported side effects of Imdur that involve confusion or mental fogginess?

A: Confusion is listed in official documentation as a potential symptom of severe low blood pressure or an overdose. Confusion or mental fogginess is a symptom that should be discussed with a healthcare provider.


Q: Does Imdur have any known impact on the eyes or vision?

A: Blurred vision, severe eye pain, or a sudden loss of sight is noted in patient information as a serious symptom. This may be a sign of a rare but serious condition, such as acute angle closure glaucoma, that warrants prompt medical evaluation.


Q: Can Imdur potentially interact with common over-the-counter pain medications for headache relief?

A: Regulatory sources confirm that common pain relievers like acetaminophen (paracetamol) or aspirin can often successfully relieve the medication-induced headache. Official information indicates that these over-the-counter medicines do not reduce Imdur's antianginal effectiveness.


Q: How long does it typically take for Imdur to reach its full preventive effect?

A: Clinical trials demonstrated that antianginal activity was measurable after the first dose. The medication is prescribed for continuous daily use to maintain a steady, long-term preventative effect.


Q: What is the potential impact if a dose of Imdur is missed?

A: Official instructions advise that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next dose, patients should consult their provider, as it is generally recommended to avoid taking a double dose.


Q: What is the purpose of the doctor starting a patient on a lower dose of Imdur?

A: Regulatory information explicitly states that the starting dose may be adjusted (titrated) to minimize the possibility and frequency of headaches when treatment is first initiated.


Q: Is there a possibility that Imdur could cause chest pain that is new or worse?

A: Worsening or increased angina pectoris (chest pain) is listed in official documents as a potential adverse event. This may also occur if the medication causes significant low blood pressure (hypotension).


Q: Can environmental factors like hot weather or exercise increase the risk of side effects from Imdur?

A: Regulatory documents advise caution and consulting a healthcare provider if conditions that can lead to volume depletion occur, such as excessive sweating, vomiting, or diarrhea. This caution is related to the potential for increased risk of side effects, such as low blood pressure.


Q: Are there specific instructions for how Imdur should be taken in relation to food?

A: Regulatory instructions for the extended-release tablet do not specify taking the dose with or without food. The administration method requires that the dose be swallowed whole in the morning with a fluid.


Q: Do the effects of Imdur last for 24 hours?

A: Clinical trials demonstrated that the once-daily dose provided at least 12 hours of antianginal activity. The medication is dosed once daily to ensure a necessary nitrate-free period is maintained, which is crucial for preventing the development of drug tolerance.


Q: What kind of lifestyle adjustments, if any, are generally suggested while taking Imdur?

A: Regulatory-adjacent patient information states that certain lifestyle changes, such as dietary adjustments, moderate exercise, and avoiding smoking, may help the medication work more effectively. These adjustments complement the drug's role in long-term cardiovascular maintenance.

How should Imdur be stored and disposed of?

Storage and Disposal of Imdur (Isosorbide Mononitrate)

Official regulatory labeling dictates specific conditions to maintain the stability and potency of Imdur tablets.

Storage Requirement Official Condition
Temperature Store at Controlled Room Temperature, 20 to 25 C (68 to 77 F), with excursions up to 30 C (86 F). Do not store above 30 C.
Environmental Protection Protect from light and store away from excess heat and moisture. Keep the medication in the original, tightly closed container.
Child Safety The medication must be kept out of the sight and reach of children.
Disposal Instructions Do not dispose of unused or expired Imdur via wastewater (e.g., flushing) or in household garbage. Dispose of the product according to local regulations, such as a pharmacy take-back program.

These requirements ensure the product remains stable and minimizes environmental impact during disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Imdur found in:

A-Z Index: